The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study

Dapagliflozin was associated with an increased risk of diabetic ketoacidosis that has led to the European withdrawal of the authorization for the type 1 diabetes. However, it is still used for the treatment of type 2 diabetes. Therefore, we aim to evaluate the occurrence of dapagliflozin-induced ket...

Descripción completa

Detalles Bibliográficos
Autores principales: di Mauro, Gabriella, Mascolo, Annamaria, Gaio, Mario, Rafaniello, Concetta, De Angelis, Antonella, Berrino, Liberato, Paolisso, Giuseppe, Rossi, Francesco, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952809/
https://www.ncbi.nlm.nih.gov/pubmed/35337085
http://dx.doi.org/10.3390/ph15030286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952809/
https://www.ncbi.nlm.nih.gov/pubmed/35337085
http://dx.doi.org/10.3390/ph15030286

Ejemplares similares